

Key investor information document

This document provides you with key investor information about this Fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this Fund. You are advised to read it so you can make an informed decision about whether to invest.

FIM Rohto Biomed Fund

FIM ROHTO BIOMED GROWTH UNIT (ISIN FI0008801410)
THE FUND IS MANAGED BY FIM ASSET MANAGEMENT LTD WHICH IS PART OF S-BANK LTD.



Objective and investment policy

The objective of the Fund's investment activity is to earn as high a return on the invested assets as possible over the long term through active fund management. The aim is to outperform the benchmark index, which is the MSCI Daily (tr) World Net Health Care USD return index calculated in euros. The index depicts the performance of the stocks of large and mid-cap pharmaceutical and healthcare sector companies globally. The return index also includes dividends paid by the companies.*

The assets of the Fund are invested globally in the equities of companies operating in the pharmaceuticals, biotechnology, food technology and healthcare technology sectors and companies providing healthcare services. In its investment activity, the Fund strives to use active fund management to benefit from business fluctuations within the sector. The investment decisions are primarily based on our market view and equity-specific factors, but we also actively utilise our views on the situation and prospects of the sector's subsectors.

The Fund uses derivative contracts irregularly. The derivatives used are most commonly forward exchange contracts, which are used to hedge against currency risk. The Fund does not follow the benchmark index in its investment activity, and thus its composition often differs significantly from the benchmark.

The Fund's basic currency is the euro. Units in the Fund may be subscribed for and redeemed on all Finnish banking days. The Fund has only one unit class, comprising growth units. No return is paid out to the growth units. Unitholders may redeem the units they own by notifying the fund management company of this.

*) Previously used indices: a composite of the AMEX Pharmaceutical (60%), AMEX Biotech (20%) and DJS Health Care (20%) (tr) indices until 31 Dec. 2009; a composite of the AMEX Pharmaceuticals (60%), AMEX Biotech (20%) and DJ EURO STOXX Health Care (20%) indices, calculated in euros, until 31 Dec. 2007.

More information on MSCI indexes can be found on the MSCI website (www.msci.com).

Recommendation: this fund may not be appropriate for investors who plan to withdraw their money within 7 years.

Risk and reward profile



The Fund's risk category is 6. This means there is a high risk related to the value development of the fund units. The Fund's risk category has been determined based on changes in the historical performance of a fund unit (volatility) and thus may not accurately indicate the Fund's future risk level. The Fund's risk category may rise or diminish in the future, and even the lowest risk category does not mean the investment is completely free of risk. Fund investments carry the risk of negative value development.

The biggest individual factor affecting a fund unit's value in the short term is general stock market development. Because the Fund concentrates its investments on a specific sector, the risk and reward expectations of the Fund's investments are higher than average. FIM's fund management style, which is proactive and follows our own market vision, may also have a considerable impact on the value of the Fund, especially when compared to other similar products. The Fund carries a currency risk as investments are primarily made in currencies other than the euro.

The risk indicator may not fully reflect the following risks:
— The use of derivative contracts may increase the Fund's counterparty and operational risk. The use of derivatives for hedging purposes may diminish the Fund's risk and expected return. The use of derivatives for obtaining additional returns may increase the Fund's risk and expected return.
— For further information on risks related to securities lending, see the fund prospectus.

Charges

One-off charges taken before or after you invest

Entry charge	-
Exit charge	-

This is the maximum that might be taken out of your money before the proceeds of your investment are paid out.

Charges taken from the Fund over each year

Ongoing charge	1.83 %
----------------	--------

Charges taken from the Fund under certain specific conditions

Performance fee	-
-----------------	---


The charges paid by the investor are used to pay for the costs of running the Fund, including the costs of marketing and distributing the Fund. The charges reduce the potential return of the investment.

The charges stated are the maximum charges that may be charged for the Fund or in conjunction with an event. In some cases, the charges may be lower. Information about the actual charges is available at request from the fund management company.

The on-going charges figure is based on expenses for the year 2018 and they comprise compensation paid to the fund management company and custodian. This figure may vary from year to year. The charges do not include performance-based fees or trading fees paid by the Fund, apart from potential subscription and redemption fees paid for buying or selling units in another fund.

The management/custody fee paid to the fund management company/custodian will be deducted from the value of the fund unit class/fund in conjunction with the value calculation and paid to the fund management company/custodian monthly in arrears.

Past performance



The Fund began operations on 8.5.2000.

The graph shows the annual percentage changes in the value of the fund unit. The Fund's annual performance has been calculated after expenses, in euros. Subscription or redemption related fees or taxes have not been taken into account when calculating the performance.

The Fund's past performance does not guarantee future returns. The value of the investments may increase or decrease and investors may lose the invested assets in total or partly.

Practical information

Further information about the Fund can be obtained from the fund prospectus, the Fund rules, and the annual and semiannual reports of FIM Funds. These are available free of charge on the FIM websites, www.fim.com and www.fim.se, in Finnish and in Swedish. The fund unit NAV is calculated on all Finnish banking days and published on the FIM websites.

The Fund's custodian: Skandinaviska Enskilda Banken AB (publ) filial i Helsingfors.

Minimum investment in the Fund is 500 kronor.

The tax legislation applied in the Fund's home state may affect the investor's personal income taxation.

Information about fund management company's remuneration policy is in the fund prospectus.

This document is a translation. If there are any discrepancies between the translation and the original Finnish document, the Finnish document will prevail.

The rules of the Fund have been confirmed on 14 January 2016 in Finland and are in force as of 1 March 2016. FIM Asset Management Ltd is authorised to operate in Finland. The Fund and the fund management company are regulated by the Finnish Financial Supervisory Authority.

FIM Asset Management Ltd may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the Fund.

This key investor information document is part of the comprehensive prospectus and in force as of 10 May 2019.